Literature DB >> 16370960

The safety and efficacy of antithyroid drugs.

Fereidoun Azizi1.   

Abstract

Thionamides, selective inhibitors of thyroid peroxidase-mediated iodination by tyrosine residues in thyroglobulin, have been effectively used in the treatment of hyperthyroidism. The choices for initial treatment of patients with Graves' disease differ in various countries, and many physicians around the world prefer to administer thionamide drugs as the first choice of treatment for patients with hyperthyroidism. Although some thyroidologists more often consider radioiodine to be the treatment of choice because of its safety and ease of administration, thionamides remain the mainstay of treatment in thyrotoxic children and adolescents and in hyperthyroid women during pregnancy, postpartum period and lactation. A recent study with continuous thionamide treatment for patients with Graves' disease shows its efficacy, safety and cost-benefit properties. Further studies of the effectiveness of continuous thionamide therapy in patients with thyrotoxicosis need to be designed and implemented to determine indications for such therapy in children, adolescents and adults with diffuse toxic goiter, in particular, in those who have had recurrence of hyperthyroidism after discontinuation of one complete course of treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16370960     DOI: 10.1517/14740338.5.1.107

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  11 in total

1.  Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum.

Authors:  Alex Stagnaro-Green; Marcos Abalovich; Erik Alexander; Fereidoun Azizi; Jorge Mestman; Roberto Negro; Angelita Nixon; Elizabeth N Pearce; Offie P Soldin; Scott Sullivan; Wilmar Wiersinga
Journal:  Thyroid       Date:  2011-07-25       Impact factor: 6.568

2.  The efficiency and safety of methimazole and propylthiouracil in hyperthyroidism: A meta-analysis of randomized controlled trials.

Authors:  Shuang Tan; Long Chen; Likun Jin; Xiaomin Fu
Journal:  Medicine (Baltimore)       Date:  2021-07-30       Impact factor: 1.817

Review 3.  Hyperthyroidism.

Authors:  Simone De Leo; Sun Y Lee; Lewis E Braverman
Journal:  Lancet       Date:  2016-03-30       Impact factor: 79.321

4.  Clinical study of renal impairment in patients with propylthiouracil-induced small-vessel vasculitis and patients with primary ANCA-associated small-vessel vasculitis.

Authors:  Xiaozhi Cao; Weiyuan Lin
Journal:  Exp Ther Med       Date:  2013-04-15       Impact factor: 2.447

5.  Propylthiouracil-induced ANCA-negative cutaneous small vessel vasculitis.

Authors:  Aliaksandr Trusau; Michael L Brit
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-02-06

Review 6.  Hyperthyroidism in the pregnant woman: Maternal and fetal aspects.

Authors:  Mariacarla Moleti; Maria Di Mauro; Giacomo Sturniolo; Marco Russo; Francesco Vermiglio
Journal:  J Clin Transl Endocrinol       Date:  2019-04-12

7.  The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves' Disease Patients Through Regulating the Intestinal Microbiome.

Authors:  Zhe Han; Chaoping Cen; Qianying Ou; Yonggui Pan; Jiachao Zhang; Dongxue Huo; Kaining Chen
Journal:  Front Immunol       Date:  2022-01-10       Impact factor: 7.561

8.  Propylthiouracil induced leukocytoclastic vasculitis: A rare manifestation.

Authors:  Semra Ayturk; Mustafa Volkan Demir; Selçuk Yaylacı; Ali Tamer
Journal:  Indian J Endocrinol Metab       Date:  2013-03

9.  Thyroid hormone increases fibroblast growth factor receptor expression and disrupts cell mechanics in the developing organ of corti.

Authors:  Katherine B Szarama; Núria Gavara; Ronald S Petralia; Richard S Chadwick; Matthew W Kelley
Journal:  BMC Dev Biol       Date:  2013-02-09       Impact factor: 1.978

10.  Propylthiouracil-induced autoimmune disease.

Authors:  Santosh Paiaulla; Pradeep Marur Venkategowda; S Manimala Rao; Banda Balaraju
Journal:  Indian J Crit Care Med       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.